PsyBio Therapeutics (PSYBF)

Acquisition of Everest Pharma Adds Broad Ex-US License


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
March 21, 2022
Report ID: 24593
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


PsyBio Therapeutics
PsyBio Therapeutics
Healthcare
Biotechnology
Ticker
PSYBF
Current Price
$0.04385 30.7%
Market Cap
$4.9M
Price Target
Refer to Report
Volume
1.5K
52wk Range
$0.029 - $0.2925
Related Research Reports
3/21/2022

Acquisition of Everest Pharma Adds Broad Ex-US License
Acquisition of Everest Pharma Adds Broad Ex-US License (PSYBF)
10/14/2021

PsyBio Continues To Report Development Milestones
PsyBio Continues To Report Development Milestones (PSYBF)
8/9/2021

Initiating Coverage With A $2 Price Target
Initiating Coverage With A $2 Price Target (PSYBF)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.